SEC EDGARJUN 11 min read$PGEN

Sabzevari Helen sold $520K of PGEN

Sabzevari Helen (President and CEO) sold 119,250 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.52M total) on 2026-05-28.

Original reporting

SEC EDGAR · Sabzevari Helen

Published Jun 1, 2026, 8:25 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 1, 2026, 8:38 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$PGEN

Neutral

medium confidence

Mentioned

$PGEN

Relevance

7/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PGENNeutralLow

Why it matters

Traders may treat the disclosure as a small sentiment datapoint; without new guidance, trial, or financial results, it typically has limited predictive power.

Market read

Insider selling disclosure can slightly pressure sentiment, but lacks fundamental follow-through in the article.

What to watch

No 10b5-1 plan is cited, but the filing alone does not reveal intent, future trading windows, or whether additional insider sales/buys occurred around the same period.

Relevance 7/10Novelty 6/10Timing: After-hours/next-session read-through from 2026-05-28 sale disclosed on 2026-06-01

Background

The article summarizes a newly filed SEC Form 4 insider transaction for Precigen (PGEN).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PGENNeutralMedium confidence

Context

SEC Form 4 shows CEO Sabzevari Helen sold 119,250 shares of Precigen at $4.36 on 2026-05-28.

Expected impact

Likely limited near-term impact; any move would be sentiment-driven rather than fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying company-specific operational or financial news; also notes no 10b5-1 plan.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide development.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may reflect diversification, liquidity needs, or routine compensation taxes rather than a bearish view, especially since the transaction is disclosed as an open-market sale.

Key entities

issuer
PRECIGEN, INC.
Company whose CEO filed the insider sale disclosure.
insider
Sabzevari Helen
President and CEO who sold shares via open-market sale.

Read at source ← All news

AUG 4

$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

SEC EDGAR 8-K6 min

JUN 23

$PGENMed

Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason

Precigen Inc. (PGEN) rose 11.62% to close at $5.38 on Monday for a second straight session. The gain followed the company’s late-month FDA approval granting six-year orphan drug exclusivity for Papzimeos to treat recurrent respiratory papillomatosis in the U.S., extending protection until Aug. 14, 2032, according to Precigen.

finance.yahoo.com3 min

JUN 1

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

newswise.com4 min

MAY 30

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e

prnewswire.com4 min

AUG 8

$ATTOLow